Motexafin lutetium

Motexafin lutetium
Names
	Other names Antrin; Lu texaphyrin; Lu-Tex; Lutetium texaphyrin; Lutrin; Optrin; PCI 0123
Identifiers
CAS Number	246252-04-0 ;
3D model (JSmol)	Interactive image;
PubChem CID	3081907;
UNII	0V38NF6N89 ;
	SMILES CC([O-])=O.CCC1=C2[N-]C(/C=C3N=C(/C=N/C4=CC(OCCOCCOCCOC)=C(OCCOCCOCCOC)C=C4/N=C/C(C(C)=C/5CCCO)=[N]([Lu+3])C5=C/2)C(C)=C\3CCCO)=C1CC;
Properties
Chemical formula	C52H72LuN5O14
Molar mass	1166.136 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	verify (what is ?)
	Infobox references

Motexafin lutetium is a texaphyrin, marketed as Antrin by Pharmacyclics Inc.

It is a photosensitiser for use in photodynamic therapy to treat skin conditions and superficial cancers.

It has also been tested for use in photoangioplasty (photodynamic treatment of diseased arteries).[1]

It is photoactivated by 732 nm light which allows greater depth of penetration.[2]

Clinical trials

Phase II clinical trials were in progress in 1999.[3]

A phase I trial for prostate cancer reported in 2009.[4]

gollark: Presumably, all tile entities ceased to exist.

gollark: Probably, all computers have been deleted via some bug or other.

gollark: It's at 20 TPS? Impossible.

gollark: Only 1/∞ instead of 0?

gollark: Also, the SC community, if it could somehow all be on a kitchen sink server, would probably result in basically the same thing but with more automation and stuff.

References

Pharmacyclics Announces Final Phase 1 Results of Antrin Phototherapy For Coronary Artery Disease Archived 2011-07-16 at the Wayback Machine, 2002
http://findarticles.com/p/articles/mi_qa3931/is_200909/ai_n42040200/pg_9/ Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy Photochemistry and Photobiology, Sep/Oct 2009. by O'Connor, Aisling E, Gallagher, William M, Byrne, Annette T
Antrin Photoangioplasty Phase II Clinical Trial Patient Treated During Live Case Demonstration at TCT Archived 2012-07-13 at Archive.today, 1999
Patel, H; Mick, R; Finlay, J; Zhu, TC; Rickter, E; Cengel, KA; Malkowicz, SB; Hahn, SM; Busch, TM (2008). "Motexafin lutetium-photodynamic therapy of prostate cancer: Short and long term effects on PSA". Clinical Cancer Research. 14 (15): 4869–76. doi:10.1158/1078-0432.CCR-08-0317. PMC 2680073. PMID 18676760.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Pharmacyclics Announces Final Phase 1 Results of Antrin Phototherapy For Coronary Artery Disease Archived 2011-07-16 at the Wayback Machine, 2002

[2] ttp://findarticles.com/p/articles/mi_qa3931/is_200909/ai_n42040200/pg_9/ Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy Photochemistry and Photobiology, Sep/Oct 2009. by O'Connor, Aisling E, Gallagher, William M, Byrne, Annette T

[3] Antrin Photoangioplasty Phase II Clinical Trial Patient Treated During Live Case Demonstration at TCT Archived 2012-07-13 at Archive.today, 1999

[4] Patel, H; Mick, R; Finlay, J; Zhu, TC; Rickter, E; Cengel, KA; Malkowicz, SB; Hahn, SM; Busch, TM (2008). "Motexafin lutetium-photodynamic therapy of prostate cancer: Short and long term effects on PSA". Clinical Cancer Research. 14 (15): 4869–76. doi:10.1158/1078-0432.CCR-08-0317. PMC 2680073. PMID 18676760.